Koyfin Home > Directory > Health Care > Acceleron Pharma > Total Equity

Acceleron Pharma Total Equity Chart (XLRN)

Acceleron Pharma annual/quarterly Total Equity from 2012 to 2020.
  • Acceleron Pharma Total Equity for the quarter ending June 06, 2020 was $422m a -10.24% decrease of -43m year over year
  • Acceleron Pharma Total Equity for the last 12 months ending June 06, 2020 was $422m a -10.24% decrease of -43m year over year
  • Acceleron Pharma Annual Total Equity for 2019 was $449m a 35.03% increase of 157m from 2018
  • Acceleron Pharma Annual Total Equity for 2018 was $292m a -25.06% decrease of -73m from 2017
  • Acceleron Pharma Annual Total Equity for 2017 was $365m a 38.23% increase of 140m from 2016
Other Balance Sheet Metrics:
  • Acceleron Pharma Total Assets for the quarter ending September 09, 2018 was $338m a -15.10% decrease of -51m year over year
  • Acceleron Pharma Other Liabilities for the quarter ending December 12, 2018 was $4m a 14.46% increase of 1m year over year
View Chart On Koyfin

Quarterly XLRN Total Equity Data

06/2020$422m
03/2020$414m
12/2019$449m
09/2019$465m
06/2019$500m
03/2019$511m
12/2018$292m
09/2018$319m
06/2018$333m
03/2018$354m

Annual XLRN Total Equity Data

2019$449m
2018$292m
2017$365m
2016$226m
2015$109m
2014$156m
2013$58m
2012$-21m
2011$10m